New CTIX writeup in Seeking Alpha by ChemistFrog: 'Top

New Post Public Reply Private Reply Replies (2) Message Board
TheProgressive
New CTIX writeup in Seeking Alpha by ChemistFrog:

'Top Of The Class' Small Pharma Investments For 2013 Part II

seekingalpha.com/article/1118281

Small Pharma Leader in Small Molecule Approach to Fighting Cancer

Cellceutix Corporation (CTIX.OB) long time investors have enjoyed a solid stock run up in the last month, with shares reaching 52-week highs of $2.47 after the company traded below a dollar as recently as late November. The share price increase has come as a result of promising news on its lead drug candidate, Kevetrin™, a small molecule drug that reactivates tumor suppressor protein p53. Once reactivated (cancer cells have a way of inhibiting p53), p53 induces the expressions of p21 and PUMA (p53 up-regulated modulator of apoptosis). This reactivation inhibits cancer cell growth and causes tumor cell apoptosis (programmed cell death).

Volume and share price interest for the company's common shares started to pick up after the company's December 3rd announcement that the phase 1 Kevetrin™ dose escalation trial was progressing well with 84 blood samples from the patients being been sent to a laboratory for pharmacokinetics analysis (an evaluation of how the drug is absorbed, distributed, metabolized, and excreted from the body). A follow up December 14th announcement from the company confirmed that it was allowed to continue with the next higher dose of Kevetrin™, with dosing to begin on December 16th. Shares continued to climb to the $2.50 resistance mark on December 26-27th after a December 24th response by CEO, Leo Ehrlich, to a December 23rd story in the New York Times titled "Genetic Gamble; New Approaches to Fighting Cancer" and its focus on p53. The New York Times story went on to discuss p53 as the "Guardian Angel Gene" and mentioned work by Merck (MRK), Roche Holding Ltd. (RHHBY.PK) and Sanofi SA (SNY) in "racing to develop their own versions of a drug they hope will restore a mechanism that normally makes badly damaged cells self-destruct and could potentially be used against half of all cancers." Although obviously disappointed that Cellceutix was not mentioned in the piece, I'm certain Mr. Ehrlich appreciated the exposure for the novel approach to the publication's large readership. Important for interested shareholders going forward was a statement by Mr. Ehrlich in his response noting "I believe that a discerning examination of the article and publicly available information shows that we are not only ahead of these larger companies, but we have a better mechanism which is more likely to function against most cancers. Our research to date shows that Kevetrin™ affects both wild and mutant types of p53, a claim that to the best of our understanding, the other companies cannot make." If clinicals underway confirm this statement, the company's common shares as well as the targeted patient groups (not yet to be determined) could each benefit.

A December 31st company update gives much information that should be considered as the company heads into 2013 with a now $2.00 share price and $186 million market capitalization. With Kevetrin™ in multiple trials, Mr. Ehrlich gave indications of multiple catalysts ahead for the company in 2013 with trial updates and data presentations likely. Company-sponsored clinical trials at Harvard University's Dana-Farber Cancer Center and Beth Israel Deaconess Medical Center, which began in November, are evaluating the drug's safety with pharmacokinetics from the early cohort expected in the short-term. Trials evaluating Kevetrin™ for Acute Myelogenous Leukemia (AML) and sponsored by "a leading European university" are expected to being in 1H 2013. Data presentations by the company as well as its partners will be significant although these are early stage clinicals. With Merck, Roche, and Sanofi each developing drugs using similar technologies, positive and applicable news from any or each of these companies will also likely have impacts on the company's share price. Additionally, positive Kevetrin™ data could also begin turning large pharmaceutical companies' heads, with licensing or buyout potential also becoming evident for the early-stage company before its valuation starts ramping up under its own merit.

Although beyond the scope of this article, investors should also consider the company's lead product candidate, Plurisol™, with phase 2 trial preparations now underway evaluating the drug's safety/efficacy to treat psoriasis. If the FDA approves the company forgoing early-stage clinicals and allows it to instead start with a phase 2 trial, the company could save much time and money moving forward to its first likely marketable product. Cellceutix is also planning on starting a "proof of concept" trial for Plurisol™ in Q1 2013 in the European Union, which could also affect share price in the coming weeks.

A development-phase company, Cellceutix is still largely dependent on shareholder money to fund its operations with the ever-looming fear of dilution in the thoughts of its investors. However, a December 10th announcement by the company of a $10 million stock purchase agreement with Aspire Capital Fund, LLC gave terms of some of the best financing agreements I have personally ever seen with a small pharmaceutical company . Aspire would buy $10 million of the company's common shares over the next three years at market price with Cellceutix determining the timing and number of shares to purchase. Terms of the deal indicated no restrictions on the funds, financial covenants, restrictions on future financings, rights of first refusal, participation rights, penalties, or liquidated damages per the agreement. Cellceutix did issue 336,625 common shares to Aspire for consideration of the agreement; however, no warrants were part of the agreement. With cash and equivalents of only $125,000 on September 30th, the financing certainly helps to secure the company and its growing pipeline.

Cellceutix common shares are now trading at $2.00 at the time of this composition, above the simple moving average (SMA) with technical support seen at $1.75. Although a "watch and wait" approach may often serve investors better for solid entries, the pharmacokinetics results for Kevetrin™ are still pending and may send share prices upward once again. Alternately, poor or questionable results may also give interested investors a better entry soon thereafter as the data may or may not indicate efficacy or safety accurately. With the company's recent news serving as the major catalyst for recent price increases, interested investors should also consider the risk of downside if clinicals don't yield positive data. Many indications are potentially going to be evaluated, and failure in one indication does not necessarily failure for another. Also consider, the company's Kevetrin™ platform is in early clinicals with marketing potential still years away, but that is typically considered and expected in the small pharma sector and has likely been taken into consideration with the company's $186 million market capitalization.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 34

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 37

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 39

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 122

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 280

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 22

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 75

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 111

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

Luckbox Stock Reaches New Low: Market Movements Explained

Updated Category News Views 326

Luckbox Stock Performance Overview The gaming and esports betting company, Luckbox, is currently navigating a fluctuating market landscape, with its stock price recently dipping to a notable 52-week low of $9.68. This shift is a pronounced departure from the previous year, reflecting ongoing challenges within the industry. As of now, the company's market capitalization...

Continue Reading
Nota AI and Renesas: Revolutionizing Driver Monitoring Technology

Updated Category News Views 153

Collaboration Between Nota AI and Renesas Nota AI, known for its expertise in AI optimization, has announced an exciting partnership with Renesas Electronics Corporation, aiming to advance driver monitoring technology through the optimized Driver Monitoring System (DMS). This collaboration is particularly focused on the new RA8P1 microcontroller unit (MCU), which is...

Continue Reading
Mirum Pharmaceuticals Presents Promising LIVMARLI Data at Conference

Updated Category News Views 107

Mirum Pharmaceuticals showcases LIVMARLI research findings Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has announced its participation in a significant scientific meeting where it aims to present groundbreaking data on LIVMARLI® (maralixibat) oral solution. This event is hosted by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition...

Continue Reading
Genmab Stock Faces Challenges, Yet Holds Hope for Recovery

Updated Category News Views 130

Genmab Stock Overview Genmab A/S Sponsored ADR (NASDAQ: GMAB) has recently experienced a turbulent period, with a notable decline of 14.7% in just four weeks. However, this decline has left the stock in an oversold position, igniting hope among investors as analysts anticipate improved earnings results. Understanding Oversold Conditions To assess whether a stock, such as...

Continue Reading
Challenges Ahead for Central Banks Tackling Inflation Variability

Updated Category News Views 117

Challenges Ahead for Central Banks in Addressing Inflation Fluctuations Inflation is a complex issue for policymakers, as recent comments from European Central Bank President Christine Lagarde illustrate. With substantial changes happening in the global economy, the prospect of stable inflation remains uncertain. Lagarde suggests that inflation may experience significant...

Continue Reading